Hepatocellular Carcinoma Video Perspectives

In a video interview, Amit Singal, MD, professor of internal medicine and chief of hepatology at UT Southwestern Medical Center, discussed:

• latest trends and developments in the treatment of hepatocellular carcinoma, including new studies that have shown effective and well-tolerated alternatives to sorafenib (Nevaxar, Bayer), such as atezolizumab (Tecentriq, Genentech) and bevacizumab (Avastin, Genentech);
• changing risk factors for developing HCC over time, with an emphasis on the effects of existing alcoholic liver disease and cirrhosis;
• strategies for improving early detection of HCC, including the growing need for Americans to be aware of the disease and participate in screening;
• causes of the growing impact of HCC in the United States, where the rate of HCC development has steadily grown over the last four decades;
• development of new immunotherapies in HCC treatment, and the outlook for what further study in the area could provide in the future;
• and impact of hepatitis treatments on HCC, and the role an effective and well-tolerated hepatitis B vaccine plays in HCC treatment.